Results from the phase III study of nadofaregene firadenovec: Safety and efficacy in patients with high-grade, BCG-unresponsive Non-Muscle Invasive Bladder Cancer

Speaker: N. Shore, Myrtle Beach (US)   Event: 35th Annual EAU Congress – Virtual (EAU20V)
 
0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *